Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 57

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 57
---
3,300,000 |     | Execute full IND-enabling package for Nano-Mupirocin, initiate tech transfer to CDMO, and fund      
 expanded preclinical studies for Nano-Candesartan.                                                  |
| If 1,562,500 Units, or 100%, are 
 sold                             |     | $ | 4,400,000 |     | Complete GMP manufacturing and submit IND for Nano-Mupirocin. Conduct Phase 1 trial. Fully fund     
 preclinical activities for Nano-Candesartan and working capital.                                    |

Set forth below are the estimated amounts we intend
to allocate to each of our product candidates efforts, assuming the full amount of the Primary offering is raised

| Program         |     | Expected                 
 Allocation               |     | Planned                                                                                          
 Use                                                                                              |     | Further                                            
 Funding Required                                   |
| Nano-Mupirocin  |     | $2,420,000 (approx. 55%) |     | Finalize GMP manufacturing process (CMC), bioanalytical                                          
 methods, IND-enabling toxicology studies, and initiate Phase 1 Clinical Trial.                   |     | Yes – ~$3.5M additional funding needed for         
 Phase 1.                                           |
| Nano-ARB        |     | $1,100,000 (approx. 25%) |     | Conduct large-animal                                                                             
 PK/PD and BP safety studies, initial tumor model studies, and scale-up manufacturing assessment. |     | Yes – ~$2M needed to complete IND-enabling         
 studies.                                           |
| General & Admin |     | $880,000 (approx. 20%)   |     | Salaries, legal, IP, audit, and other operating                                                  
 costs.                                                                                           |     | Covered by proceeds; no additional funds required. |

If we raise less than the full offering amount,
we intend to prioritize activities related to our lead program (Nano-Mupirocin), and delay or reduce certain planned expenditures, including
clinical trial initiation, until additional financing becomes available.

To fully execute the Phase 1 and 2 clinical trial
for Nano-Mupirocin and to advance the Nano-ARB program through IND-enabling studies, we may require additional funds beyond the net proceeds
of this offering. We intend to pursue such funding through additional financings, strategic partnerships, or non-dilutive sources such
as grants.

The use of the proceeds represents management’s
estimates based on current business and economic conditions.